Agenus shared a post on LinkedIn:
“For many patients with CRC, treatment still means chemotherapy, surgery, and significant impact on quality of life.
At AACR2026, the BBOpCo investigator-sponsored study led by Nicholas DeVito explores a different approach: Using immunotherapy earlier in the disease course to harness the body’s own immune system.
This first-line study of BOT+BAL in MSS metastatic colorectal cancer reflects a growing effort to rethink how – and when – we treat.
Because patients deserve options that go beyond the status quo.
Full details.”
Other articles from Agenus.